Showing 8051-8060 of 9932 results for "".
- ASDSA Alerts Nation’s Governors to New Trend in Anti-transgender Legislationhttps://practicaldermatology.com/news/asdsa-alerts-nations-governors-to-new-trend-in-anti-transgender-legislation/2460749/The American Society for Dermatologic Surgery Association (ASDSA) sent a letter to all 50 state governors along with legislative leaders, alerting them to the increase in anti-transgender legislation that is proliferating in state legislatures across the country. After Arkansas be
- Expert Opinion: Fleshing Out the Role of Biosimilars in Dermatologyhttps://practicaldermatology.com/news/expert-opinion-fleshing-out-the-role-of-biosimilars-in-dermatology/2460742/Two new studies of biosimilars of tumor necrosis factor blockers that are used to treat a number of dermatologic conditions suggest that they are equivalent to their originator drugs, but there may be more involved in making the decision about switching to a biosimilar than lower cost.
- Practical Dermatology Magazine Mourns the Passing of Two Preeminent Dermatologistshttps://practicaldermatology.com/news/practical-dermatology-mourns-the-passing-of-two-preeminent-dermatologists/2460741/By Wendy Lewis It is with great sadness that Practical Dermatology® magazine pays our respects to two very talented and respected dermatologists, Melanie Grossman, MD and Marta Rendon, MD.
- Galderma's Nemolizumab Performs Well in Phase 2b for ADhttps://practicaldermatology.com/news/galdermas-nemolizumab-performs-well-in-phase-2b-for-ad/2460739/Investigational nemolizumab led to rapid and sustained improvements in itch, sleep, and skin lesions in adult patients with uncontrolled moderate-to-severe AD in phase 2 studies published in Journal of the European Academy of Dermatology and Venereology (JEADV) and reported by
- Hydrafacial Expands CONNECT Certification Programhttps://practicaldermatology.com/news/hydrafacial-expands-connect-certification-program/2460733/The HydraFacial Company is expanding the HydraFacial CONNECT certification program, making it available to aesthetic professionals nationwide. This past month, the program successfully graduated its first class of CONNECT Masters, the highest distinction in the certification progr
- About Three-Quarters of Americans Wish They Had Taken Better Care of Themselves During the Pandemichttps://practicaldermatology.com/news/about-three-quarters-of-americans-wish-they-had-taken-better-care-of-themselves-during-the-pandemic/2460732/Seventy-four percent of people say they wish they’d taken better care of themselves this past year, including many admitting to sub-par skincare and grooming, finds a new survey of more than 2,022 people by
- Journey Medical to Acquire Dermira's Qbrexzahttps://practicaldermatology.com/news/journey-medical-to-acquire-dermiras-qbrexza/2460731/Journey Medical Corporation, a partner company of Fortress Biotech, Inc., has entered into a definitive agreement to acquire Qbrexza (glycopyrronium) in the US from Dermira, Inc., a wholly-owned subsidiary of Eli Lilly and Company. The transaction is expected to close early in the secon
- AAD Honors Dr. Ginette Okoye with National Patient Care Hero Award for COVID-19 Testing Workhttps://practicaldermatology.com/news/aad-honors-dr-ginette-okoye-with-national-patient-care-hero-award-for-covid-19-testing-work/2460729/The American Academy of Dermatology (AAD) named board-certified dermatologist Ginette Okoye, MD, FAAD a Patient Care Hero for establishing a dedicated COVID-19 community testing site in a historically underserved neighborhood in northeast Washington, DC. Amid the initial surge in COVID-
- Dermata Doses First Patient in Phase 1b Trial of Topical DMT310 for Mild-to-Moderate Psoriasishttps://practicaldermatology.com/news/dermata-doses-first-patient-in-phase-1b-trial-of-topical-dmt310-for-mild-to-moderate-psoriasis/2460726/Dermata Therapeutics, Inc. dosed its first patient in a Phase 1b trial of DMT310 for the treatment of mild-to-moderate psoriasis. DMT310 is currently being investigated to treat multiple inflammatory skin diseases. It consists of a once-weekly topical treatment with both mech
- NRS Launches Updated Version of "Understanding Rosacea" for Patientshttps://practicaldermatology.com/news/nrs-launches-updated-version-of-understanding-rosacea-for-patients/2460721/The National Rosacea Society has updated its most popular educational booklet. The new edition of “Understanding Rosacea” incorporates the updated standard classification and pathophysiology of rosacea, developed by a consensus committee and review panel of 28 rosacea experts worldwid